Animal Pharm is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By



Set Alert for Pharmaceuticals

Agile Sciences believes it can 're-energize' animal health's faith in antibiotics

Agile Sciences claims its naturally-sourced compounds could reinvigorate the use of antibiotics against drug-resistant bacterial infections. Malcolm Thomas – chief executive of the Raleigh, North Carolina-based start-up – told Animal Pharm editor Joseph Harvey how the company's technology might impact the animal health sector.

Pharmaceuticals R&D

Elanco 'prepared' for generics competition from Huvepharma

Elanco has said it is prepared for off-patent competition, after Huvepharma was recently given the green light by the US FDA for the first generic monensin for certain indications in cattle and goats.

Elanco Product Approvals

Merck gains Estrumate US supplemental approval

The US FDA has handed a supplemental approval to Merck Animal Health for its Estrumate (cloprostenol injection) reproductive injectable for cows.

Merck MSD Animal Health Zoetis

Experts outline ramifications of revised European bioequivalence studies guideline

Cemile Jakupoglu of Cyton Germany and Maggie Fisher of the UK's Veterinary Research Management give Animal Pharm an overview of the major changes involved in the revised EU guideline on the conduct of bioequivalence studies for veterinary medicinal products, which came into play this year.

Policy & Regulation Pharmaceuticals

UK industry body determines Boehringer in breach of code on vaccine promotion

The UK's National Office of Animal Health (NOAH) has found Boehringer Ingelheim to be in breach of code on its promotion of a cattle vaccine. 

Boehringer Ingelheim Animal Health Policy & Regulation

KindredBio plans parvovirus mAb launch in next two years, claims 'blockbuster' pipeline potential

Kindred Biosciences chief executive Richard Chin has said the firm is aiming to launch its monoclonal antibody candidate against canine parvovirus by the end of 2020 or early 2021. 

Kindred Biosciences R&D

Troy Labs becomes Animal Medicines Australia member

Industry body Animal Medicines Australia (AMA) has added its 10th member – Troy Laboratories. 

Australia Policy & Regulation

Dechra secures rights to once-a-week canine diabetes injectable through licensing deal

Dechra Pharmaceuticals has signed an intellectual property licensing and supply agreement for an insulin-based product candidate that it believes could become a top-seller in its portfolio.

Dechra Pharmaceuticals Deals

KindredBio sees wider net loss, reveals new mAb targeting canine parvovirus

Kindred Biosciences has once again seen its quarterly net loss increase, as it continues to advance its pipeline. 

Kindred Biosciences Financial Results

FDA approves extra indications for finfish treatment

The US FDA has authorized additional indications for Syndel's 35% PEROX-AID – an over-the-counter treatment for freshwater finfish.

United States FDA

Zoetis to establish livestock immunotherapy lab at Colorado State Uni

Zoetis has signaled a different approach to collaboration with academia by preparing to create a research laboratory at Colorado State University (CSU).

Zoetis United States

Penn Vet to lead a trial on cannabinoid effectiveness for canine joint immobility

The University of Pennsylvania School of Veterinary Medicine (Penn Vet) will lead a clinical trial to assess whether a hemp-based natural supplement can relieve symptoms of joint immobility in dogs.

Canine Pharmaceuticals
See All